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Abstract
Age-related macular degeneration (AMD) is a progressive retinal disorder affecting over 33 million people worldwide.
Genome-wide association studies (GWASs) for AMD identified common variants at 19 loci accounting for 15–65% of the
heritability and it has been hypothesized that the missing heritability may be attributed to rare variants with large effect
sizes. Common variants in the complement component 3 (C3) gene have been associated with AMD and recently a rare C3
variant (Lys155Gln) was identified which exerts a large effect on AMD susceptibility independent of the common variants.
To explore whether additional rare variants in the C3 gene are associated with AMD, we sequenced all coding exons in 84
unrelated AMD cases. Subsequently, we genotyped all identified variants in 1474 AMD cases and 2258 controls.
Additionally, because of the known genetic overlap between AMD and atypical hemolytic uremic syndrome (aHUS), we
genotyped two recurrent aHUS-associated C3 mutations in the entire cohort. Overall, we identified three rare variants
(Lys65Gln (P= 0.04), Arg735Trp (OR= 17.4, 95% CI = 2.2–136; P= 0.0003), and Ser1619Arg (OR= 5.2, 95% CI = 1.0–25; P= 0.05)
at the C3 locus that are associated with AMD in our EUGENDA cohort. However, the Arg735Trp and Ser1619Arg variants
were not found to be associated with AMD in the Rotterdam Study. The Lys65Gln variant was only identified in patients
from Nijmegen, the Netherlands, and thus may represent a region-specific AMD risk variant.
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Introduction
Age-related macular degeneration (AMD, MIM 603075) is a
retinal disorder that causes progressive visual impairment in
individuals aged over 50 years [1]. AMD primarily affects the
macula, the central region of the retina, eventually leading to loss
of central and sharp vision. It has been estimated that more than
33 million people suffer from vision loss due to AMD worldwide
[2]. AMD is a multifactorial disease caused by a combination of
genetic and environmental factors. GWASs identified common
variants at 19 loci that influence disease susceptibility, accounting
for 15–65% of the heritability [3,4].
It has been hypothesized that the remaining genetic fraction
influencing the risk for development of AMD, the so-called missing
heritability, may be explained by rare, highly penetrant variants
[4]. Simulation studies suggested that common variants are
insufficient to account for disease burden in densely affected
AMD families and that rare penetrant variants would offer a likely
explanation [5]. In addition, a meta-analysis of AMD GWASs
suggested that each of the 19 loci may harbour several
independent variants associated to AMD susceptibility [3]. The
rare variant hypothesis is supported by the identification of rare
missense mutations in the fibulin-5 (FBLN5) gene and the
hemicentin-1 (HMCN1) gene in AMD patients [6,7]. In addition,
rare, highly penetrant variants in the genes encoding complement
factor H (CFH), complement factor I (CFI), complement compo-
nent 3 (C3) and complement component 9 (C9) have recently been
found to be associated with AMD [8–12].
Genetic studies have identified an important role for the
complement cascade in the pathogenesis of AMD [13]. Interest-
ingly, recent studies suggested a genetic overlap between AMD
and atypical hemolytic uremic syndrome (aHUS), a life-threaten-
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ing renal disease caused by chronic, uncontrolled activation of the
complement system. It has been reported that 4–10% of aHUS
patients carry mutations in the C3 gene [14]. Moreover, disease-
causing mutations previously identified in aHUS patients, such as
Arg1210Cys in CFH, Gly119Arg in CFI and Lys155Gln in C3
were found to confer a high risk of developing AMD [8–12].
However, the precise nature of this genetic overlap between two
clinically distinct phenotypes remains unknown.
In this study, we explored the role of rare variants in the C3
gene in the pathogenesis of AMD. We performed a two-stage
analysis to identify rare variants in the C3 gene. First, sequence
analysis was carried out in a discovery set of 84 AMD cases from
the EUGENDA cohort, and subsequently the frequencies of these
variants were determined in replication sets from EUGENDA and
from the Rotterdam Study consisting of 1474 AMD cases and
2258 controls. In addition, two recurrent aHUS-associated C3
mutations were genotyped in the entire AMD case-control cohort
[15,16].
Results
To investigate the involvement of rare variants in the C3 gene in
AMD, the exons and flanking introns of C3 were sequenced in a
discovery cohort of 84 AMD cases (Table 1) from the Nijmegen
area, the Netherlands. Sequencing identified three rare variants
(MAF,1%; Lys155Gln/rs147859257, Arg735Trp/rs117793540
and Ser1619Arg/rs2230210) and two common variants
(MAF$1%; Arg102Gly/rs2230199 and Pro314Leu/rs1047286)
(Table 2). None of the rare variants were found in 192 ethnicity-
matched and age-matched controls. The Lys155Gln variant,
which has recently been associated with AMD [10–12], was found
in five cases, while variants Arg735Trp and Ser1619Arg were
found in one case each. Bioinformatic algorithms SIFT and
PolyPhen predicted the variants Arg102Gly, Lys155Gln, and
Pro314Leu not to be damaging whereas Arg735Trp and
Ser1619Arg were predicted to be damaging to the protein
function (Table 2).
Next, the frequencies of the rare variants Arg735Trp and
Ser1619Arg, as well as the common variants Arg102Gly and
Pro314Leu were determined, in replication cohorts from EU-
GENDA and from the Rotterdam Study, consisting of 1474 AMD
cases and 2258 controls of European ancestry (Table 3). In
addition, two recurrent aHUS mutations (Lys65Gln and
Arg161Trp) were included in the analysis (Table 3). The common
variants Arg102Gly (OR=1.2 [95% CI 1.1–1.4]; P=0.001) and
Pro314Leu (OR=1.2 [95% CI 1.0–1.4]; P=0.005) were signif-
icantly associated with AMD. In the EUGENDA cohort, the rare
variant Arg735Trp was found heterozygously in 8 and homozy-
gously in one out of 718 AMD cases and heterozygously in one out
of 1246 controls (OR=17.4 [95% CI 2.2–136]; P=0.0003).
However, in the Rotterdam Study the rare variant Arg735Trp was
found heterozygously in 1 out of 785 AMD cases and hetero-
zygously in 2 out of 1048 controls, and was thus not associated
with the disease. Rare variant Ser1619Arg was found hetero-
zygously in six out of 718 AMD cases and heterozygously in two
out of 1244 controls in the EUGENDA cohort (OR=5.2 [95% CI
.1.0–25]; P=0.05). In the Rotterdam Study the rare variant
Ser1619Arg was found heterozygously in 6 out of 835 AMD cases
and heterozygously in 11 out of 1279 controls, and was thus not
associated with AMD. The aHUS mutation Lys65Gln was found
heterozygously in three out of 717 AMD cases and was not
observed in 1246 controls (P=0.05) in the EUGENDA cohort, but
was not identified in the Rotterdam Study. Arg161Trp was found
heterozygously in two out of 644 AMD cases and was not observed
in 1142 controls (P=0.13) in the EUGENDA cohort. In the
Rotterdam Study the aHUS mutation Arg161Trp was observed
heterozygously in one out of 320 AMD cases and heterozygously
in one out of 483 controls (P=1.0), and was not significantly
associated with AMD in the EUGENDA cohort nor in the
Rotterdam Study.
To determine whether the identified variants conferred disease
risk independent of the two known common C3 variants
(Arg102Gly/rs2230199 and Pro314Leu/rs1047286), a conditional
logistic regression analysis was performed (Table 4). After
conditioning on Arg102Gly/rs2230199, Arg735Trp remained
associated with disease risk in the EUGENDA cohort
(OR=22.1, 95% CI= 2.8–173; P=0.003). Similarly, after condi-
tioning on Pro314Leu/rs1047286, Arg735Trp still showed asso-
ciation with disease risk in the EUGENDA cohort (OR=22.0,
95% CI=2.8–172; P=0.003). In addition, Arg735Trp was
significantly associated with disease risk in the EUGENDA cohort
(OR=22.1, 95% CI= 2.8–173; P=0.003) after conditioning on
both variants (Arg102Gly and Pro314Leu). Independent associa-
tion with AMD could not be assessed for Lys65Gln and
Ser1619Arg because too few data points were available to perform
a reliable conditional analysis.
Discussion
In this study, three rare variants (Lys65Gln, Arg735Trp and
Ser1619Arg) in the C3 gene were shown to be associated with
AMD disease risk in our EUGENDA cohort. However, the
Arg735Trp and Ser1619Arg variants were not found to be
associated with AMD in the Rotterdam Study. The Arg735Trp
and Ser1619Arg variants were also not associated with AMD in a
recent study that analyzed the C3 gene in 2,493 AMD cases and
controls [10]. The Lys65Gln variant was only identified in AMD
patients from the Nijmegen area, while it was not found in the
Rotterdam Study, nor in a cohort from Boston [10]. The
Lys65Gln variant may therefore represent a region-specific
AMD risk variant, being confined to the east of the Netherlands,
which is confirmed by the occurrence of Lys65Gln in Dutch
aHUS patients [16]. A fourth variant, Arg161Trp, was found in
three AMD cases and in one control; therefore it cannot be ruled
out that the variant is in fact associated with AMD but a larger
sample size would be required to detect a significant association.
The complement system plays an important role in the
pathogenesis of AMD [8–12]. The C3 gene encodes the
complement component 3 protein, a central component of the
complement cascade that plays a crucial role in clearance of
Table 1. Demographics of studied subjects.
Variables EUGENDA cohort Rotterdam Study
Cases Controls Cases Controls
Controls (n) 1246 1012
Intermediate AMD (n) 173 636
Advanced AMD (n) 545 120
Mean age (6SD) 7668 7065.9 8066.4 7766.5
Gender
Male 271 532 354 497
Female 447 714 402 515
EUGENDA: a multicenter database comprising participants from Germany and
the Netherlands.
doi:10.1371/journal.pone.0094165.t001
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pathogens and immune complexes. All three branches of the
complement system, the classical pathway, the mannose-binding
lectin pathway and the alternative pathway, converge at C3. At
this stage, activation of C3 results in an amplification loop that
ultimately forms a cytolytic membrane attack complex which
targets pathogens. The system is tightly controlled by molecules
like CFH and CFI. If the complement cascade is improperly
regulated, host cells may also be subjected to complement attack,
resulting in tissue damage and a spectrum of complement-
mediated diseases [17].
The rare variants reported in this study have previously been
described for their association with aHUS, a chronic renal
disorder caused by uncontrolled activation of the complement
system, often leading to renal failure. Functional experiments have
been performed in this context to determine the effect of the
amino acid substitutions on C3 function. The Lys65Gln variant
resides in the macroglobulin (MG1) domain of C3 and was shown
to cause decreased binding to CFH [16]. Although not signifi-
cantly associated in our study, the Arg161Trp variant was shown
to cause hyperactive C3 convertase due to increased binding to
factor B (CFB), and reduced binding to CFH and membrane
cofactor protein (MCP; CD46), resulting in higher complement
activity [15,16,18].
Recombinant protein studies have shown that the Arg735Trp
variant performs normal in binding and cleavage assays [14].
However, since the Arg735Trp residue is located in the
anaphylotoxin (C3a) domain of C3, it is not likely to show an
effect in the performed assays that evaluated binding and
activation of the C3b fragment. Recent studies in animal models
suggest that C3a anaphylotoxin has specific functions in the retina
and retinal pigment epithelium, but it remains unknown how an
amino acid substitution in C3a may contribute to the development
of AMD [19,20].
The Lys65Gln variant associated with AMD in this study has
previously been associated with aHUS, further supporting the
genetic overlap between AMD and aHUS. To rule out any renal
pathology, the medical histories of AMD patients who carried this
variant were evaluated, but no signs of aHUS or other renal
pathologies were reported in these patients. Thus, although aHUS
and AMD may overlap genetically, in this study no clinical overlap
was shown, suggesting that compounding (genetic or environmen-
tal) factors contribute to a particular clinical phenotype. Such a
notion is further supported by a study that showed that some
aHUS patients carry multiple mutations in the complement factor
genes [21]. In order to understand the shared associations, cross-
phenotype studies are warranted to unravel the mechanisms
common and unique to aHUS and AMD. This will lead to more
rational approaches to diagnosis and therapy by targeting these
specific molecular targets.
The identification of rare penetrant AMD-associated variants
may have relevance for diagnostic, predictive and therapeutic
purposes, although the exact interpretation may remain a
challenge. Recent studies have identified several highly penetrant
rare variants (Lys155Gln in C3, Gly119Arg in CFI, Pro167Ser in
C9 and Arg1210Cys in CFH), to be associated with AMD [8–12].
However, not all associations hold true among different popula-
tions. An example of this is the Arg1210Cys variant in CFH which
was strongly associated in a North American AMD cohort [8] but
not in an Icelandic AMD cohort [11] (Table 5). Genetic drift,
founder effects or differences in genetic make-up that could
compensate for a rare disruptive variant may underlie this
phenomenon. In addition, the possibility that environmental
effects could mask or enhance the penetrance of certain alleles
between populations may also exist. To date, it remains unclear
how these observations impact the predictive value of finding such
variants in individuals. In contrast, variants that were proven to be
functionally impaired and that are associated with AMD in several
populations, such as the Lys155Gln variant in C3, have a much
stronger predictive value.
In conclusion, we report a rare variant (Lys65Gln) at the C3
locus in patients with AMD, while an association with two other
variants (Arg735Trp and Ser1619Arg) was not confirmed in other
cohorts. This study further supports that rare variants contribute
to the genetic variance of AMD, which may have implications for
predictive testing and personalized medicine in AMD [10].
Materials and Methods
Cases and controls
Cases and controls included in this study were selected from the
population-based Rotterdam Study, Rotterdam, The Netherlands
and from the European Genetic Database (EUGENDA), a
multicenter database comprising participants from the Cologne
area, Germany and the Nijmegen area, the Netherlands. All
participants of this study underwent extensive retinal imaging
which has been described in detail elsewhere [22,23]. In short,
AMD staging was performed by grading of stereo fundus
photographs according to the standard protocol of the Rotterdam
grading center and Cologne Image Reading Center (CIRCL). All
subjects were classified on the basis of the eye with the more severe
diagnosis. Cases were aged $50 years of age and AMD was
classified by the presence of at least 15 intermediate (63–124 mm)
Table 2. C3 variants identified by sequence analysis of 84 AMD cases.
SNP ID Sequence variants Genotypes Prediction algorithms
Nucleotide change Amino acid change Mm mm SIFT PolyPhen2
rs2230199 c.304 C.G Arg102Gly 34 11 Tolerated (0.5) Tolerated (0)
rs1047286 c.941 C.T Pro314Leu 30 10 Tolerated (0.1) Tolerated (0.2)
rs147859257 c.463 A.C Lys155Gln 5 0 Tolerated (0.2) Benign (0.1)
rs117793540 c.2203 C.T Arg735Trp 1 0 Deleterious (0) Damaging (1)
rs2230210 c.4855 A.C Ser1619Arg 1 0 Deleterious (0) Damaging (0.8)
Major and minor allele indicated in capital and lower case respectively.
Reference sequence of C3 (NM_000064) gene.
SIFT: Sorting Intolerant from Tolerant (Intolerance #0.05).
PolyPhen2: Polymorphism Phenotyping (score 0R1).
doi:10.1371/journal.pone.0094165.t002
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or at least one large drusen ($125 mm) or geographic atrophy or
choroidal neovascularisation secondary to AMD. Control subjects
were aged $65 years of age and did not have AMD (none or only
small, hard drusen or only pigmentary abnormalities or less than
10 small drusen and pigmentary abnormalities). Written informed
consent was obtained from all participants. The EUGENDA
study was approved by the local research ethics committee,
Commissie Mensgebonden Onderzoek Regio Arnhem-Nijmegen,
the Netherlands, and Ethics Committee of the University
Hospital Cologne, Germany. The Rotterdam study was approved
by the institutional review board (Medical Ethics Committee) of
the Erasmus Medical Center and by the review board of The
Netherlands Ministry of Health, Welfare and Sports. The study
was performed in accordance with the tenets of the Declaration
of Helsinki.
Sequencing
Sanger sequencing of the C3 (NM_000064) gene was performed
in the discovery set, consisting of 84 AMD patients selected from
the EUGENDA database. Primers were designed for all 41 coding
exons and intron-exon boundaries by Primer3 software (Supple-
mentary Material, Table S1). Polymerase chain reaction (PCR)
was performed, and PCR amplicons were sequenced using an
automated sequencer (BigDye Terminator, version 3, 3730 DNA
analyzer; Applied Biosystems). Sequences were assembled and
analysed using ContigExpress (Vector NTI Advance, Version
11.0, Life Technologies). Each newly identified variant was
confirmed by a second independent PCR and bidirectional Sanger
sequencing. The predicted effects of identified missense variants
were examined using Polymorphism Phenotyping (PolyPhen) [24]
and Sorting Intolerant from Tolerant (SIFT) [25].
Genotyping in the EUGENDA cohort
Variants (Lys65Gln, Arg102Gly, Arg161Trp, Pro314Leu, and
Arg735Trp) were genotyped in the EUGENDA cohort using
competitive allele-specific PCR assays (KASPar SNP Genotyping
System, KBiosciences). KASPar genotyping was performed
according to the manufacturer’s protocol in a volume of 4 ml
containing 10 ng of genomic DNA, 2.5 ml of 26reaction mix, and
0.069 ml of assay. Thermal cycling conditions included a pre-
incubation step at 94uC for 15 min, 20 cycles of 94uC for 10 s,
57uC for 5 s, 72uC for 10 s, followed by 23 cycles of 94uC for 10 s,
57uC for 20 s, 72uC for 40 s. Plates were analyzed on a 7900 Fast
Real-Time PCR system (Applied Biosystems). The Ser1619Arg
variant was genotyped in the EUGENDA cohort by Amplification
Refractory Mutation System (ARMS) [26] PCR (Supplementary
Material, Table S2). PCR reactions were performed in a volume of
12.5 ml using 20 ng genomic DNA, 16 buffer, 2.5 mM MgCl2,
1 mM deoxyribonucleotide triphosphates, 0.2 mM of each primer,
and 0.5 U Taq DNA polymerase (Invitrogen, Life technologies).
Thermal cycle conditions included a pre-incubation step at 95uC
for 5 min, 16 cycles of 95uC for 30 s, 69uC for 30 s, 72uC for 45 s,
followed by 25 cycles of 95uC for 30 s, 67uC for 30 s, 72uC for
45 s. PCR amplicons were analysed by agarose gel electrophoresis.
Each newly identified variant was confirmed by a second
independent PCR and bidirectional Sanger sequencing.
Exome sequencing, exome chip analysis and genotyping
in the Rotterdam Study
The occurrence of the C3 variants Lys65Gln, Arg161Trp,
Arg735Trp, and Ser1619Arg in the Rotterdam Study (RS) was
retrieved from exome chip and exome sequencing data. For exome
sequencing purposes, genomic DNA of RS participants was
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prepared from blood and fragmented into 200–400 bp fragments
using Covaris Adaptive Focused Acoustics (AFA) shearing
according to the manufacturer’s instructions (Covaris, Inc.,
Woburn, MA). Illumina TruSeq DNA Library preparation
(Illumina, Inc., San Diego, CA) was performed on a Caliper
Sciclone NGS workstation (Caliper Life Sciences, Hopkinton,
MA), followed by exome capture using the Nimblegen SeqCap
EZ V2 kit (Roche Nimblegen, Inc., Madison, WI). This capture
targets 44 Mb of exonic regions covering 30,246 coding genes,
329,028 exons and 710 miRNAs. Paired-end 26100 sequencing
was performed on Illumina HiSeq2000 sequencer using Illumina
TruSeq V3 chemistry. Downstream analyses included demulti-
plexing (CASAVA software, Illumina), alignment using the
burrows-wheeler alignment tool, followed by data processing
and filtering with Picard, SAMtools and the Genome Analysis
Tool-Kit [27,28]. Finally, variant detection was performed using
GATK’s Unified Genotyper. For exome chip analysis, DNA
samples of the Rotterdam study were included in the joint calling
experiment of the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE) Consortium [29]. In short,
DNA from the study participants was processed on the
HumanExome BeadChip v1.0 (Illumina, Inc, San Diego, CA)
querying 247,870 variable sites using standard protocols at seven
genotyping centers. Each center genotyped a common set of 96
HapMap samples to be utilized for quality control and
determination of batch effects. Raw datafiles for all samples
were transferred to a central location and assembled into a single
joint calling (Illumina GenomeStudio v2011.1 software and
GenTrain 2.0 clustering algorithm). Call rates .99% were used
for both study samples as for HapMap controls to define
genotype clusters. Finally 8994 variants were excluded for further
analyses. Common variants (Arg102Gly and Pro314Leu) were
genotyped in the RS cohort using Taqman assays (Applied
Biosystems, Foster city, California, USA).
Statistical analysis
A Fisher’s exact test was performed to assess the association
between each variant and AMD, and also to check for Hardy-
Weinberg equilibrium. P-values were calculated two-sided, and
values of ,0.05 were considered as statistically significant. Logistic
Table 5. Rare variants in AMD studies.
Gene Variant Study (Population) Functional implication Conclusions
Present study
C3 Lys65Gln NL CFH binding Q [16] Associated with AMD, not present in other
populations, proven functionality, reported in
aHUS [16]
Arg161Trp NL CFH binding Q, CFB binding q
[15,16,18]
Not associated with AMD, proven
functionality, reported in aHUS [15,16,18]
Arg735Trp NL Normal binding [14] Not associated with AMD, normal
functionality, reported in aHUS [14]
Ser1619Arg NL NA Not associated with AMD, not proven
functionality, not found in aHUS
Other studies
C3 Lys155Gln ISL, NL, GER, USA [10,11,12] CFH binding Q [18] Associated with AMD, replicated in several
populations, proven functionality, reported in
aHUS [18]
CFI Gly119Arg NL, USA [9] CFI activity Q [9] Associated with AMD, replicated in different
populations, proven functionality, reported in
aHUS [9,30]
C9 Pro167Ser FRA, USA [10] NA Associated with AMD, replicated in different
populations [10]
CFH Arg1210Cys USA [8] C3b, heparin and endothelial
cells binding Q [31]
Associated with AMD, not present in other
populations, proven functionality, reported in
aHUS [31]
NL: The Netherlands, ISL: Iceland, GER: Germany, USA: United states of America, FRA: France.
NA: Not applicable.
doi:10.1371/journal.pone.0094165.t005
Table 4. Conditional analysis of Arg735Trp for SNPs Arg102Gly/rs2230199 and Pro314Leu/rs1047286.
Condition EUGENDA cohort Combined cohorts (EUGENDA and Rotterdam)
OR (95%CI) p-value OR (95%CI) p-value
Arg102Gly/rs2230199 22.1 (2.8–173) 0.003 6.2 (1.7–22.5) 0.005
Pro314Leu/rs1047286 22.0 (2.8–172) 0.003 6.2 (1.7–22.4) 0.005
Arg102Gly & Pro314Leu 22.1 (2.8–173) 0.003 6.2 (1.7–22.5) 0.005
EUGENDA: a multicenter database comprising participants from the Cologne area, Germany and the Nijmegen area, the Netherlands.
doi:10.1371/journal.pone.0094165.t004
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regression analysis was performed to check for genotype interac-
tions, to estimate the odds ratios (OR) with 95% confidence
intervals (CI) and to adjust for age. Conditional analysis was
performed to identify secondary association signals at the C3 locus
by accounting for two known AMD SNPs. Either Arg102Gly/
rs2230199 or Pro314Leu/rs1047286 was added independently
and combined to the regression model as a covariate to test the
effect of the variant of interest. Data were analyzed using SPSS
software, version 18.0.
Supporting Information
Table S1 List of C3 gene sequencing primers.
(DOC)
Table S2 Genotyping probes: List of Amplification
Refractory Mutation System (ARMS) and kaspar prim-
ers.
(DOC)
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